Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report.
Future Oncol
; 15(24s): 27-33, 2019 Aug.
Article
em En
| MEDLINE
| ID: mdl-31393171
ABSTRACT
Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Quinolinas
/
Anormalidades Cardiovasculares
/
Câncer Papilífero da Tireoide
/
Hipertensão
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Itália